# Drug Therapy Protocols: Oxytocin

<table>
<thead>
<tr>
<th><strong>Policy code</strong></th>
<th>DTP_OXYT_0722</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Date</strong></td>
<td>July, 2022</td>
</tr>
<tr>
<td><strong>Purpose</strong></td>
<td>To ensure a consistent procedural approach to oxytocin administration.</td>
</tr>
<tr>
<td><strong>Scope</strong></td>
<td>Applies to all Queensland Ambulance Service (QAS) clinical staff.</td>
</tr>
<tr>
<td><strong>Health care setting</strong></td>
<td>Pre-hospital assessment and treatment.</td>
</tr>
<tr>
<td><strong>Population</strong></td>
<td>Applies to all ages unless specifically mentioned.</td>
</tr>
<tr>
<td><strong>Source of funding</strong></td>
<td>Internal – 100%</td>
</tr>
<tr>
<td><strong>Author</strong></td>
<td>Clinical Quality &amp; Patient Safety Unit, QAS</td>
</tr>
<tr>
<td><strong>Review date</strong></td>
<td>July, 2024</td>
</tr>
</tbody>
</table>

While the QAS has attempted to contact all copyright owners, this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome. Please forward to: Clinical.Guidelines@ambulance.qld.gov.au

**Disclaimer**

The Digital Clinical Practice Manual is expressly intended for use by appropriately qualified QAS clinicians when performing duties and delivering ambulance services for, and on behalf of, the QAS.

The QAS disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this manual, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.

© State of Queensland (Queensland Ambulance Service) 2022.
Oxytocin

Drug class
Oxytocin[^1-2]

Pharmacology
Synthetic oxytocin is a uterine stimulant that causes uterine contractions by changing calcium concentrations within uterine muscle cells. Oxytocin administered during the third stage of labour assists with placental separation, raises the tone of the uterine musculature and minimises further uterine blood loss.[^1-2]

Metabolism
Oxytocin is metabolised by the liver and excreted by the kidneys.[^1]

Indications
- Active management of the third stage of labour (following confirmed delivery of all fetuses) AND the prevention of primary post-partum haemorrhage
- Management of uncontrolled primary or secondary post-partum haemorrhage

Contraindications
- Allergy AND/OR Adverse Drug Reaction
- Undelivered fetuses

Precautions
- Myocardial ischaemia
- May potentiate hypotension when administered with analgesia

Side effects
- Nausea and/or vomiting
- Headache
- Bradycardia
- Tachycardia

Presentation
- Ampoule, 10 International units (IU) / 1 mL

Onset | Duration | Half-life
--- | --- | ---
IM 2–4 minutes | 30–60 minutes | N/A
• When oxytocin is administered for the management of the third stage of labour, multiple births must be excluded prior to the drug being administered.

• Oxytocin is only to be administered to the consenting patient who agrees to an active management of the third stage of labour. Women who prefer a physiological management must birth the placenta unaided, by maternal effort and the natural force of gravity.

• To allow for the benefits of delayed cord clamping it is acceptable to do a modified active third stage management by waiting until the cord has stopped pulsating to administer oxytocin. This is particularly important in neonatal resuscitation where the baby is resuscitated between the birthing parent's legs (where appropriate) to receive the benefit of a pulsing cord and placental perfusion.

• Skin to skin contact and initiation of breastfeeding should occur in addition to the use of uterotonic medications to promote natural oxytocin release and promote normothermia, maternal/neonatal bonding and early breastfeeding.

**Special notes**

• Ambulance officers must only administer medications for the listed indications and dosing range. Any consideration for treatment outside the listed scope of practice requires mandatory approval via the QAS Clinical Consultation and Advice Line.

• GH Oxytocin is only stable at room temperature for 3 months following delivery – for further information please refer to the QAS Drug Management Code of Practice.

• Latex allergy may be an important predisposing risk factor for anaphylaxis following oxytocin administration.

• The use of uterotonics for the prevention of postpartum haemorrhage during the third stage of labour is recommended for all births.\[1\]
**Adult dosages**

**Active management of the third stage of labour**
(following confirmed delivery of all fetuses) **AND**
the prevention of primary post-partum haemorrhage

- **IM**
  - 10 International Units
  - Single dose only.

**Management of uncontrolled primary or secondary post-partum haemorrhage**

- **IV**
  - Loading dose – 10 International Units
    - Slow push over 2–5 minutes.
    - May be given in addition to a dose that may have been administered for: Active management of the third stage of labour/the prevention of primary PPH.
  - **INF**
    - Maintenance dose – 10 International Units/hour

**Infusion preparation:** Mix 10 International Units oxytocin (1 mL) with 19 mL of sodium chloride 0.9% in a 20 mL syringe to achieve a final concentration of 10 International Units/20 mL. Ensure syringe is appropriately labelled. Administer infusion via Perfusor® space at 20 mL/hr.

**Paediatric dosages**

**Note:** QAS officers are **NOT** authorised to administer oxytocin to paediatric patients.